-
Here are 6 money making ideas from technical analysts that may deliver good gains in the near term.
-
The company recently informed bourses that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for expanding access to Lilly’s drug, baricitinib in India
-
Government may sell up to 5.8 crore shares at the floor price of Rs 680 per share, and raise up to Rs 3,949.34 crore via OFS
-
Shares of the company traded 4.44% down at Rs 317.60 at around 10 am (IST). On the other hand, the benchmark BSE Sensex was up 28 points, or 0.06%, at 50,221 at around the same time.
-
Here are 6 money making ideas from technical analysts that may deliver good gains in the near term.
-
The company's existing range of Covid-19 therapeutics cover the full spectrum from mild to moderate and severe conditions of the disease
-
Calling it a stock picker's market, the brokerage firm advised investors prefer domestic cyclicals
-
Gland Pharma has purchased assets from a biologics company for Rs 90 crore and will be spending around Rs 180 crore additionally to develop & manufacture vaccines
-
With an investment of over Rs 400 crore, Rakesh Jhunjhunwala is one of the biggest individual shareholders in Federal Bank
-
Shares of the company have climbed 198% to Rs 5,630 on May 18 (at 10.30 am) from Rs 1,887.30 on August 17 last year. On the other hand, the benchmark BSE Sensex has gained 30% during the same period